Senior Managers Of Novartis Japan Units Replaced In Drug-Trial Scandal
This article was originally published in PharmAsia News
Executive Summary
Hours after it confirmed employee misbehavior in a clinical trial of one of its drugs in Japan, Novartis arranged the ouster of several senior managers at its local units.
Hours after it confirmed employee misbehavior in a clinical trial of one of its drugs in Japan, Novartis arranged the ouster of several senior managers at its local units. The Swiss-based company said several senior managers had resigned, calling the actions its own probe found unacceptable and violations of the company's code of conduct. David Epstein, head of the pharmaceutical division, also repeated an apology for its workers' actions during the trial. Michael Ferris, an adviser to Novartis Pharma, is to replace Hiroko Ishikawa as president of Novartis Holdings Japan, Dirk Kosche, Novartis Oncology's head of emerging markets, becomes head of Novartis Pharma to replace Yoshiyasu Ninomiya. (Click here for more - a subscription may be required
)
"Novartis Reshuffles Top Japan Staff Amid Research Scandal" - Nikkei (Japan)(4/4/2014)